Monograph Details
|
|
Endocrine System
> Diabetes
|
|
BYETTA |
| Manufacturer |
|
Amylin and Lilly |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Incretin mimetic. |
| Generic Name |
|
Exenatide 250micrograms/mL; soln for SC inj; contains m-cresol and mannitol. |
| Indications |
|
As adjunct to metformin, a sulfonylurea, a thiazolidinedione, or in combination with metformin and a sulfonylurea or with metformin and a thiazolidinedione in patients with type 2 diabetes without adequate glycemic control. |
| Children |
Not recommended.
|
| Adults |
|
Give by SC inj into thigh, abdomen, or upper arm within 60 minutes before AM and PM meals. Initially 5micrograms twice daily; may increase to 10micrograms twice daily after 1 month. |
| Contraindications |
|
Type 1 diabetes. Not for treatment of diabetic ketoacidosis. Postprandial administration. |
| Precautions |
|
Not a substitute for insulin. Severe GI disorders, renal impairment (CrCl <30mL/min): not recommended. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Consider reducing concomitant sulfonylurea dose. Concurrent insulin, D-phenylalanine derivatives, meglitinides, α-glucosidase inhibitors: not recommended. Hypoglycemia possible with sulfonylurea. May delay absorption of oral drugs (take these 1 hour before exenatide). Monitor warfarin. |
| Adverse Reactions |
|
GI upset, hypoglycemia, dizziness, headache, asthenia, reduced appetite, weight loss, GERD, hyperhidrosis; antibody formation (glycemic response may be attenuated). |
| How Supplied |
Prefilled pen (needles not included): 5micrograms/dose—1 (60 doses)
10micrograms/dose—1 (60 doses) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
